Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 77.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,763 shares of the biopharmaceutical company's stock after selling 79,349 shares during the period. Lazard Asset Management LLC's holdings in Vanda Pharmaceuticals were worth $113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth approximately $1,296,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth approximately $1,221,000. Dimensional Fund Advisors LP increased its stake in shares of Vanda Pharmaceuticals by 10.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company's stock worth $11,920,000 after buying an additional 227,428 shares during the period. Monaco Asset Management SAM increased its stake in shares of Vanda Pharmaceuticals by 92.8% during the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock worth $1,879,000 after buying an additional 188,836 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Vanda Pharmaceuticals by 108.9% during the fourth quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company's stock worth $1,608,000 after buying an additional 175,019 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

VNDA has been the topic of a number of recent research reports. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Finally, Wall Street Zen started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a "hold" rating on the stock.

Vanda Pharmaceuticals Price Performance

Shares of VNDA traded up $0.09 during mid-day trading on Thursday, reaching $4.40. The company's stock had a trading volume of 59,339 shares, compared to its average volume of 620,607. Vanda Pharmaceuticals Inc. has a 12-month low of $3.81 and a 12-month high of $6.75. The stock has a market cap of $259.01 million, a PE ratio of -13.73 and a beta of 0.69. The company's 50 day moving average is $4.33 and its 200 day moving average is $4.60.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The business had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. As a group, sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Insider Activity at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average cost of $4.76 per share, with a total value of $47,600.00. Following the transaction, the chief executive officer now directly owns 2,361,730 shares in the company, valued at $11,241,834.80. This trade represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders bought a total of 50,000 shares of company stock valued at $226,200 in the last three months. 10.00% of the stock is currently owned by company insiders.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.